MAM
CHRS icon

Meeder Asset Management’s Coherus Oncology CHRS Stock Holding History

Meeder Asset Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-199
Closed -$2K – 1003
2022
Q3 		$2K Buy
199
+7
+4% +$71 ﹤0.01% 1800
2022
Q2 		$1K Buy
192
+89
+86% +$774 ﹤0.01% 1992
2022
Q1 		$1K Buy
+103
New +$1.31K ﹤0.01% 2153
2021
Q4 		– Sell
-75
Closed -$1K – 1371
2021
Q3 		$1K Buy
+75
New +$1.1K ﹤0.01% 2290
2021
Q2 		– Sell
-5
Closed – – 2523
2021
Q1 		$0 Hold
5
– – ﹤0.01% 2368
2020
Q4 		$0 Hold
5
– – ﹤0.01% 1922
2020
Q3 		$0 Sell
5
-4,248
-100% -$79K ﹤0.01% 2193
2020
Q2 		$77K Sell
4,253
-2,712
-39% -$45.9K 0.01% 820
2020
Q1 		$114K Buy
6,965
+4,696
+207% +$86.8K 0.01% 680
2019
Q4 		$40K Buy
2,269
+1,795
+379% +$33.1K ﹤0.01% 1089
2019
Q3 		$10K Sell
474
-16,258
-97% -$325K ﹤0.01% 1532
2019
Q2 		$369K Buy
+16,732
New +$291K 0.03% 459
2018
Q1 		– Sell
-99
Closed -$1K – 1587
2017
Q4 		$1K Buy
+99
New +$1.06K ﹤0.01% 1554
2017
Q2 		– Sell
-224
Closed -$5K – 1678
2017
Q1 		$5K Buy
224
+171
+323% +$4.21K ﹤0.01% 1057
2016
Q4 		$1K Sell
53
-466
-90% -$13K ﹤0.01% 950
2016
Q3 		$14K Buy
+519
New +$14.2K ﹤0.01% 700

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Meeder Asset Management's CHRS Position: Q4 2022 in Review

Meeder Asset Management sold out of Coherus Oncology (CHRS) in Q4 2022, closing a stake of 199 shares — an estimated $2K sold.

Meeder Asset Management first reported a position in CHRS in Q3 2016 and held it in 16 quarters. The position peaked at $369K in Q2 2019. 161 funds tracked by Wall St. Rank hold CHRS as of Q4 2022.

  • Meeder Asset Management reported no remaining Coherus Oncology position as of Q4 2022 after selling out during the quarter.
  • Meeder Asset Management sold 199 Coherus Oncology shares in Q4 2022, an estimated $2K.
  • Meeder Asset Management first reported a position in Coherus Oncology in Q3 2016 and held it in 16 quarters.
  • Meeder Asset Management's Coherus Oncology position peaked at $369K in Q2 2019.
  • 161 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2022.

Based on Meeder Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.